Physician profile
Donna E West
NPI 1851368880
$2,097.64
in general payments reported to CMS, 2019-2025
29 companies · $343 in 2025
The $343 reported for 2025 was more than what 75% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $53.79 · 2021: $207 · 2022: $371 · 2023: $368 · 2024: $426 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $214.80 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.01 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $168.98 | 2019-2022 | |
| Lilly USA, LLC | $149.78 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Alkermes, INC. | $147.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $124.17 | 2019-2024 | Xarelto, Spravato |
| Nevro Corp. | $101.71 | 2022-2024 | Senza |
| Phathom Pharmaceuticals, INC. | $94.92 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.31 | 2019-2020 | |
| Amgen INC. | $79.75 | 2019-2023 | Repatha |
| Novo Nordisk INC | $72.45 | 2021-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $64.61 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lundbeck LLC | $57.21 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $55.11 | 2022-2025 | Zoryve, Livalo |
| Merck Sharp & Dohme LLC | $54.19 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $52.68 | 2021-2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $52.00 | 2023-2024 | Airsupra, Farxiga |
| Seqirus USA INC | $50.92 | 2025 | Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.79 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $42.64 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Conmed Corporation | $36.74 | 2025 | Conmed Biliary |
| Sanofi Pasteur INC. | $33.50 | 2023-2025 | |
| Abbvie INC. | $24.67 | 2024 | |
| Corcept Therapeutics | $17.97 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.95 | 2024 | |
| Glaxosmithkline, LLC. | $17.85 | 2024 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $12.66 | 2022 | |
| Almatica Pharma LLC | $11.15 | 2021 | |
| Axsome Therapeutics, INC. | $10.68 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.